Adalimumab treatment for severe recalcitrant chronic plaque psoriasis

Clinical and Experimental Dermatology

Volumn 34, Issue 7, 2009, Pages 784-788

  Ryan, C ^a   Kirby, B ^a   Collins, P ^a   Rogers, S ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CYCLOSPORIN A; EFALIZUMAB; ESTER DERIVATIVE; ETANERCEPT; FUMARIC ACID ESTER; HYDROXYUREA; INFLIXIMAB; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RETINOID; UNCLASSIFIED DRUG;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; INFECTION; INJECTION SITE REACTION; LOADING DRUG DOSE; LYMPHOCYTOPENIA; MALE; MONOTHERAPY; NEUTROPENIA; PHOTOTHERAPY; PRIORITY JOURNAL; PRURITUS; PSORIASIS SEVERITY INDEX; PSORIASIS VULGARIS; PUVA; RECALCITRANT CHRONIC PLAQUE PSORIASIS; SIDE EFFECT;

ADULT; ANTIBODIES, MONOCLONAL; DERMATOLOGIC AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PSORIASIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 70349484257     PISSN: 03076938     EISSN: 13652230     Source Type: Journal    
DOI: 10.1111/j.1365-2230.2008.03161.x     Document Type: Article

References (15)

1. Lebwohl M. Psoriasis. Lancet 2003 361 : 1197 1204.
2. Rapp SR, Feldman SR, Exum ML et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999 41 : 401 407.
3. Krueger G, Koo J, Lebwohl M et al. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient membership survey. Arch Dermatol 2001 137 : 280 284.
4. Oh CJ, Das KM, Gottlieb AB. Treatment with anti-tumor necrosis factor-α (TNF-α) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions. J Am Acad Dermatol 2000 42 : 829 830.
5. Veale DJ, Ritchlin C, Fitzgerald O. Immunopathology of psoriasis and psoriatic arthritis. Ann Rheum Dis 2005 64 (Suppl. 2 26 9.
6. Ettehadi P, Greaves MW, Wallach D. Elevated tumour necrosis factor-alpha biological activity in psoriatic skin lesions. Clin Exp Immunol 1994 96 : 146 151.
7. Victor FC, Gottlieb AB, Menter A. Changing paradigms in dermatology: tumor necrosis factor alpha (TNF-alpha) blockage in psoriasis and psoriatic arthritis. Clin Dermatol 2003 21 : 392 397.
8. Chong BF, Wong HK. Immunobiologics in the treatment of psoriasis. Clin Immunol 2007 123 : 129 138.
9. Calabrese LH. Molecular differences in anticytokine therapies. Clin Exp Rheumatol 2003 21 : 241 248.
10. Gordon KB, Langley RG, Leonardi C et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis. Double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 2006 55 : 598 606.
11. Menter A, Tyring SK, Gordon K et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 2008 58 : 106 115.
12. Saurat JH, Stingl G, Dubertret L et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008 158 : 558 566.
13. Fredriksson T, Pettersson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica 1978 157 : 238 244.
14. Papoutsaki M, Chimenti M, Costanzo A et al. Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics. J Am Acad Dermatol 2007 57 : 269 275.
15. Downs AMR. Adalimumab vs. etanercept in psoriasis. Clin Exp Dermatol 2007 32 : 593.